The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Myelofibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.
Some of the key takeaways from the Myelofibrosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years.
Myelofibrosis companies working in the treatment market are Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others, are developing therapies for the Myelofibrosis treatment
Emerging Myelofibrosis therapies in the different phases of clinical trials are- LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.
In December 2023, Geron has reached 50% enrolment in the Phase III IMpactMF clinical trial for its telomerase inhibitor, imetelstat, aimed at treating patients with relapsed/refractory myelofibrosis (MF). This randomized, open-label, controlled trial plans to enroll approximately 320 subjects with intermediate-2 or high-risk MF who have relapsed or are refractory to prior JAK inhibitor treatment. Participants will be randomized to receive either imetelstat or the best available therapy (BAT).
In November 2023, MorphoSys announced positive topline results from the Phase III MANIFEST-2 clinical trial evaluating pelabresib for myelofibrosis. The trial assessed pelabresib combined with Novartis and Incyte’s Jakafi (ruxolitinib) versus a placebo plus Jakafi in JAK inhibitor-naïve patients with myelofibrosis. The trial achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume at week 24.
In June 2023, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company innovating cancer treatments, announced the start of a pivotal Phase 3 clinical trial (XPORT-MF-034) (NCT04562389). This trial will evaluate the efficacy and safety of once-weekly 60mg selinexor combined with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
Myelofibrosis Overview
Myelofibrosis is a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells. This disease is part of a group of conditions known as myeloproliferative neoplasms. It results in extensive scarring (fibrosis) of the bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen (splenomegaly).
Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight
Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:
LNK01002: Lynk Pharmaceuticals
PU-H-71: Samus Therapeutics
TBX-2400: Taiga Biotechnologies
BMS-986158: Bristol-Myers Squibb
TP-3654: Sumitomo Pharma Oncology, Inc.
KER-050: Keros Therapeutics, Inc.
GB2064: Galecto Biotech AB
9-ING-41: Actuate Therapeutics Inc.
Selinexor: Karyopharm Therapeutics In
Navitoclax: AbbVie
Momelotinib: Sierra Oncology
Parsaclisib: Incyte Corporation
Myelofibrosis Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Myelofibrosis Molecule Type
Myelofibrosis Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Myelofibrosis Pipeline Therapeutics Assessment
Myelofibrosis Assessment by Product Type
Myelofibrosis By Stage and Product Type
Myelofibrosis Assessment by Route of Administration
Myelofibrosis By Stage and Route of Administration
Myelofibrosis Assessment by Molecule Type
Myelofibrosis by Stage and Molecule Type
DelveInsight’s Myelofibrosis Report covers around 45+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies
Some of the key companies in the Myelofibrosis Therapeutics Market include:
Key companies developing therapies for Myelofibrosis are – Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., and others.
Myelofibrosis Pipeline Analysis:
The Myelofibrosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myelofibrosis drugs and therapies
Myelofibrosis Pipeline Market Drivers
Increase in R&D for the development of new and effective drug for the treatment • Increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.
Myelofibrosis Pipeline Market Barriers
However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.
Scope of Myelofibrosis Pipeline Drug Insight
Coverage: Global
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others
Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers
Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials
Table of Contents
1. Myelofibrosis Report Introduction
2. Myelofibrosis Executive Summary
3. Myelofibrosis Overview
4. Myelofibrosis- Analytical Perspective In-depth Commercial Assessment
5. Myelofibrosis Pipeline Therapeutics
6. Myelofibrosis Late Stage Products (Phase II/III)
7. Myelofibrosis Mid Stage Products (Phase II)
8. Myelofibrosis Early Stage Products (Phase I)
9. Myelofibrosis Preclinical Stage Products
10. Myelofibrosis Therapeutics Assessment
11. Myelofibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myelofibrosis Key Companies
14. Myelofibrosis Key Products
15. Myelofibrosis Unmet Needs
16 . Myelofibrosis Market Drivers and Barriers
17. Myelofibrosis Future Perspectives and Conclusion
18. Myelofibrosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
